IsoRay, Inc. (NYSEAMERICAN:ISR) CEO Thomas C. Lavoy bought 50,000 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The shares were bought at an average cost of $0.44 per share, for a total transaction of $22,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of IsoRay stock opened at $0.43 on Monday. The stock has a market capitalization of $24.87, a price-to-earnings ratio of -3.91 and a beta of 1.22. IsoRay, Inc. has a one year low of $0.38 and a one year high of $0.69.
IsoRay (NYSEAMERICAN:ISR) last posted its quarterly earnings data on Thursday, February 8th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). IsoRay had a negative return on equity of 69.11% and a negative net margin of 95.25%. The firm had revenue of $1.54 million during the quarter.
Separately, Maxim Group set a $3.00 price objective on IsoRay and gave the stock a “buy” rating in a research report on Wednesday, January 24th.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/19/isoray-inc-isr-ceo-thomas-c-lavoy-buys-50000-shares.html.
IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.